Relmada TherapeuticsRLMD +0.80%29 EPS without NRI is $-1.09 as of Mar. 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,166 Biotechnology companies, Relmada Therapeutics ranks better than 71.1% on this metric.
Relmada Therapeutics's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was $-0.21.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.09.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 34.30% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 20.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Relmada Therapeutics's EPS without NRI or its related term are showing as below:
RLMD'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -785.8 Med: -6.55 Max: 34.3
Current: 34.3
During the past 13 years, Relmada Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 34.30% per year. The lowest was -785.80% per year. And the median was -6.55% per year.
RLMD's 3-Year EPS without NRI Growth Rate is ranked better than 71.1% of 1166
companies
in the Biotechnology industry
Industry Median: 16.65
vs RLMD: 34.30
Relmada Therapeutics's EPS (Basic) for the
three
months ended in Mar. 2026 was $-0.22.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.09.
Relmada Therapeutics (NAS:RLMD) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Relmada Therapeutics EPS without NRI Related Terms
Relmada Therapeutics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Relmada Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RLMD vs ACRS, GYRE, SGP: EPS without NRI Comparison
For the Biotechnology subindustry, Relmada Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relmada Therapeutics PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relmada Therapeutics (RLMD) has a EPS without NRI of $-1.09 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Relmada Therapeutics and its competitors. According to the industry distribution chart, Relmada Therapeutics ranks #337 out of 1166 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Relmada Therapeutics' EPS without NRI too high?
Relmada Therapeutics' current EPS without NRI is $-1.09. Based on the distribution chart, Relmada Therapeutics ranks #337 out of 1166 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' EPS without NRI compare to ACRS and GYRE?
According to the Biotechnology industry distribution chart, Relmada Therapeutics ranks #337 out of 1166 companies for EPS without NRI. This puts Relmada Therapeutics in the upper half of its industry. The industry median EPS without NRI is 16.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.65, based on 1,166 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Relmada Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relmada Therapeutics's current EPS without NRI is $-1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current EPS without NRI of $-1.09. The current EPS without NRI is $-1.09. Relmada Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current EPS without NRI is $-1.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score
Get the complete analysis for RLMD
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLMD has been successfully added to your 
